Shield Therapeutics: US Partnering Discussions Nearing Fruition
In its recent business and trading update Shield Therapeutics (STX) underlined that the US partnering discussions are progressing, which is a key factor given that the US represents around 70% of the US$3bn global iron replacement market. Therefore, this event can potentially more than double the addressable market for oral iron replacement Feraccru. While there is an ongoing review into the AEGIS-H2H 12-week trial data, longer-term 52-week study data support Feraccru’s efficacy profile, as well as data from two pivotal clinical studies. The balance sheet was recently bolstered by an US$11.4mln milestone payment from China partner ASK Pharm, providing liquidity in the months ahead to negotiate potential uncertainty owing to the coronavirus crisis.
Quick facts: Shield Therapeutics PLC
Price: 94.99 GBX
Market Cap: £111.32 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE